Weight-loss drug developer Metsera raises $290M in funding, led by ARCH Venture Partners, for obesity treatments using GLP-1 mechanism.

Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture Partners. The company is developing injectable and oral drugs for obesity using the GLP-1 mechanism and other biological targets. Metsera's GLP-1 portfolio includes an injectable in early trial stages. The market for weight-loss drugs is expected to reach at least $100 billion by the end of the decade.

April 18, 2024
3 Articles